The U.S. government has exercised options to order 1.4 million courses of the oral COVID-19 drug Molnupiravir from Merck and Ridgeback Biotherapeutics, subject to FDA approval for its emergency use. The batch will cost about $1 billion, and the government has pledged to purchase a total of 3.1 million courses of the drug worth $2.2 billion. There are also options to order more than 2 million additional courses.
The U.S. government has exercised options to order 1.4 million courses of the oral COVID-19 drug Molnupiravir from Merck and Ridgeback Biotherapeutics, subject to FDA approval for its emergency use. The batch will cost about $1 billion, and the government has pledged to purchase a total of 3.1 million courses of the drug worth $2.2 billion. There are also options to order more than 2 million additional courses. 
merck.com
English (US) 